Scientists at Cell Signaling Technology used PTMScan® Technology and a phospho-tyrosine motif antibody to analyze tyrosine kinase signaling and identify disease drivers in NSCLC cell lines and tissue samples. The study identified novel ALK-EML4 and ROS1 fusion proteins in a subset of NSCLC samples and provided the basis for the identification of patients that respond to the ALK inhibitor crizotinib1. This work resulted in the development of our highly sensitive ALK and ROS1 monoclonal antibodies.2,3
We have combined highly specific antibodies with mass spectrometry to provide proteomic services and kits to support the discovery of new mechanisms of signaling regulation by different post-translational modifications (PTMs). Currently we can support studies of acetylation, methylation, ubiquitination, Tyr phosphorylation, and Ser/Thr phosphorylation.